Problems with seasonal flu shots have been well documented,?and now U.K. biotech?Imutex?believes it has the next big?advance for flu vaccine technology.
Emergex Vaccines Holding Limited?(‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases